中国医学在调节微质极化对抗阿尔茨海默病的进展
Fengge Yang1, Wei Gao1,2, Junting Wang1,3
1Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, P. R. China.
The American journal of Chinese medicine
|December 25, 2024
概括
阿尔茨海默氏病 (AD) 涉及微质细胞 (MG),可以具有保护性或有害性. 中国医学 (CM) 在调节MG极化治疗AD方面表现有前途.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,其特点是认知能力下降和神经炎症.
- 中枢神经系统的免疫细胞微质 (MG) 在AD病变发生过程中发挥双重作用,影响粉样β清除和神经炎症.
- 目前的阿尔茨海默病治疗方法有限,这凸显了对新型治疗策略的需求.
研究的目的:
- 审查微质极化在阿尔茨海默病中的作用.
- 探索中医药在调节AD治疗中微质极化方面的治疗潜力.
主要方法:
- 文献综述综合了当前关于微质原点,极化动态和与AD病理学相互作用的知识.
- 分析中医药的治疗策略,包括单体,配方和针,用于调节微质极化.
主要成果:
- 微质极化与AD的特征密切相关,如粉样斑块,高酸化,突触功能障碍和神经炎症.
- 中国医学的干预措施显示出调节微质偏振的潜力,为阿尔茨海默病管理提供了一个有前途的途径.
- 该综述为未来临床和临床前研究关于AD的CM提供了理论框架.
结论:
- 微质极化是阿尔茨海默病进展的关键因素.
- 中国医学提供了多方面的治疗策略,可以调节微质极化,为AD治疗提供了可行的方法.
- 在临床和临床前环境中,对CM的机制和调节微质极化功效的进一步研究是有必要的.
相关概念视频
Alzheimer's Disease: Treatment
125
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
125
Alzheimer's Disease: Overview
313
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
313


